The Diagnostic Value of Cul-De-Sac Aspiration in the Detection of Ovarian Carcinoma

Funkhouser, James W.; Hunter, Karen; Thompson, N

doi:10.1097/00006254-197608000-00021

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a few stage I ovarian cancers apparently shed cytologically abnormal cells into the pelvic peritoneal fluid (5,11,14,18,19), the pain of culdocentesis repels patients, the sharp point of the needle may easily lacerate the capsule of an intact adnexal cyst, immediately spreading its contents (35), and results of cul-de-sac cytology are usually inconclusive (9,14). Therefore, we do not favor culdocentesis to obtain peritoneal cytologic specimens.…”

Section: Discussionmentioning

confidence: 99%

Early Identification, Differentiation and Treatment of Ovarian Neoplasia

Ranney

Ahmad

1979

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Among 3205 patients who needed major gynecologic operations, only 250 (7.8%) had significant ovarian cysts or tumors (170 benign, 38 "low malignant potential," 42 gross cancers). Contrary to prior reports, this study show that most patients with ovarian neoplasia had had some symptoms (duration ranged from two weeks to ten years), or a palpable adnexal mass or both. Associated symptoms have been itemized in categories. Procrastination by patients, after occurrence of the first symptoms, resulted in the growth of later-stage cancers and lower survival rates. It may be inferred from age-incidence graphs that some benign cystadenomas may be present in ovaries for long intervals of time and then may become malignant. The importance of (a) careful recording of histories, (b) periodic pelvic examinations, (c) the use of preoperative methods of differential diagnosis and (d) the differentiation between gross tumor characteristics during operations are discussed. Earlier diagnosis and treatment of ovarian neoplasia are possible and will yield better long-term results.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Identification, Differentiation and Treatment of Ovarian Neoplasia

Ranney

Ahmad

1979

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Cytologic evaluation of cervical, vaginal, or peritoneal fluids (15)(16)(17)(18), pelvic examination (19)(20)(21), transabdominal, transvaginal, and color Doppler sonography (22,23), and numerous biomarkers (24,25) have been studied as potential screening and diagnostic tests for EOC. However, these modalities are not endowed individually with sufficient test sensitivity and specificity (accuracy) to be recommended for population-based screening of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

Baron

Boardman

Lafky³

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States. Because women who are diagnosed with early stage disease have a better prognosis than women diagnosed with late stage disease, early detection represents a potentially practical approach to reduce the mortality associated with EOC. Unfortunately, no single screening test has proven to be effective for this purpose, and a valid and feasible screening program to detect early stage EOC in the general population has not yet been devised. Consequently, research has focused on coupling two or more screening modalities to improve program validity and feasibility. Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer. In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin. We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions. These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease. Hence, age-and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions. Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age-and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions. The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors. (Cancer Epidemiol Biomarkers Prev 2005;14(2):306 -18)

show abstract

“…However, these methods are generally invasive. 4 One of the non-invasive cytological methods is cytological examination of uterine cavity. This non-invasive method needs to be developed, and we attempted to develop a diagnostic method of cytology for uterine cavity.…”

mentioning

confidence: 99%

Presurgical cytologic diagnostic test of uterine cavity in ovarian malignant tumor

Andrijono¹,

Ilyas²,

Hamdani³

2005

Med J Indones

View full text Add to dashboard Cite

Ada beberapa metode untuk mendiagnosis karsinoma ovarium, diantaranya pemeriksaan ginekologi, pemeriksaan ultrasonografi, pemeriksaan tumor marker, dan gabungan beberapa pemeriksaan. Akan tetapi, gabungan pemeriksaan tersebut belum memberikan hasil spesifitas dan sensitivitas yang tinggi. Untuk itu masih diperlukan pemeriksaan lain untuk meningkatkan baik sensitivitas ataupun spesifitas, dan salah satu yang menarik untuk diteliti adalah pemeriksaan sitologi kavum uteri. Dengan pemeriksaan sitologi kavum uteri diharapkan dapat ditemukan sel-sel ganas yang berasal dari tumor ganas ovarium. Penemuan sel tumor ganas ovarium dimungkinkan karena adanya mekanisme peristaltik pada tuba fallopii dan tekanan negatif dari kavum uteri, sehingga memungkinkan terjadinya transportasi sel ganas ovarium ke dalam kavum uteri melalui tuba. Penelitian ini bertujuan mengetahui sensitivitas dan spesifitas pemeriksaan sitologi kavum uteri dalam mendeteksi keganasan ovarium dibandingkan dengan pemeriksaan histologi yang umum dilakukan. Penelitian ini merupakan uji diagnostik, dengan pemeriksaan histologi sebagai baku emas, untuk mengetahui sensitivitas, spesifisitas, nilai praduga positif, dan nilai praduga negatif pemeriksaan sitologi kavum uteri. Sebanyak 30 kasus masuk dalam penelitian ini. Ada beberapa faktor yang meningkatkan nilai positif sitologi kavum uteri, antara lain stadium, dan asites. Semakin tinggi stadium semakin besar nilai positif, adanya asites memperbesar kemungkinan positif. Pada uji diagnostik didapatkan sensitivitas sitologi kavum uteri sebesar 48%, spesifisitas 60%, nilai praduga positif 85,7%, dan nilai praduga negatif 18,8%. Kesimpulan: pemeriksaan sitologi kavum uteri dapat digunakan sebagai salah satu metode untuk membantu dalam mendiagnosis karsinoma ovarium.

show abstract

The Diagnostic Value of Cul-De-Sac Aspiration in the Detection of Ovarian Carcinoma

Cited by 3 publications

References 0 publications

Early Identification, Differentiation and Treatment of Ovarian Neoplasia

Early Identification, Differentiation and Treatment of Ovarian Neoplasia

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

Presurgical cytologic diagnostic test of uterine cavity in ovarian malignant tumor

Contact Info

Product

Resources

About